Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0000899243-22-004593 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-03 | 2022-02-01 | SPRO | Shukla Sath | CFO | A - Grant | $0.00 | +38.0K | 62.1K | +158% | $0 |
| D | 2022-02-03 | 2022-02-01 | SPRO | Shukla Sath | CFO | A - Grant | $0.00 | +53.2K | 53.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | A | A | 38,014 | $0.00 | 62,081 | D | — | — | (F1) Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. (F2) Consists of 62,081 RSUs held by the Reporting Person. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-01 | A | A | 53,190 | $0.00 | 53,190 | D | $11.18 · — to 2032-02-01 | 53,190 Common Stock | (F3) The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |